Our preliminary data suggest that standard treatment recommendations for primary ITP may be effective in patients with an active hematologic - oncologic malignancy. However, therapy responses could be significantly delayed, warranting closer monitoring. Given the pilot nature of this study and the limited sample size, these findings should be considered hypothesis-generating and require confirmation in larger studies.
Hattenhauer et al. (Wed,) studied this question.